1. Home
  2. GGG vs PYXS Comparison

GGG vs PYXS Comparison

Compare GGG & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Graco Inc.

GGG

Graco Inc.

HOLD

Current Price

$94.47

Market Cap

14.7B

Sector

Industrials

ML Signal

HOLD

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$1.32

Market Cap

71.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGG
PYXS
Founded
1926
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Fluid Controls
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.7B
71.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GGG
PYXS
Price
$94.47
$1.32
Analyst Decision
Buy
Strong Buy
Analyst Count
4
4
Target Price
$95.25
$6.75
AVG Volume (30 Days)
1.2M
678.5K
Earning Date
01-26-2026
03-17-2026
Dividend Yield
1.25%
N/A
EPS Growth
9.22
N/A
EPS
3.08
N/A
Revenue
$2,236,604,000.00
$2,820,000.00
Revenue This Year
$6.81
N/A
Revenue Next Year
$4.65
N/A
P/E Ratio
$30.61
N/A
Revenue Growth
5.83
N/A
52 Week Low
$72.06
$0.83
52 Week High
$95.69
$5.55

Technical Indicators

Market Signals
Indicator
GGG
PYXS
Relative Strength Index (RSI) 76.18 34.26
Support Level $91.71 $1.28
Resistance Level $95.69 $1.69
Average True Range (ATR) 1.89 0.12
MACD 0.45 0.02
Stochastic Oscillator 85.97 7.32

Price Performance

Historical Comparison
GGG
PYXS

About GGG Graco Inc.

Graco manufactures equipment used for managing fluids, coatings, and adhesives, specializing in difficult-to-handle materials. Graco's business is organized into three segments: industrial, process, and contractor. The Minnesota-based firm serves a wide range of end markets, including industrial, automotive, and construction, and its broad array of products include pumps, valves, meters, sprayers, and equipment used to apply coatings, sealants, and adhesives. The firm generated roughly $2.2 billion in sales in 2025.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Share on Social Networks: